Phase 3 enrollment start de-risks the AFib-RVR program and supports the single-study sNDA strategy. Monitor enrollment updates and interim data readouts. The existing CARDAMYST approval provides a commercial foundation, reducing binary risk vs. a pure pre-revenue biotech.
Price Chart
Executive Summary
Milestone Pharmaceuticals announced first patient enrollment in the Phase 3 ReVeRA-301 pivotal trial evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial uses the same 70 mg repeat-dose regimen already FDA-approved for PSVT (CARDAMYST), and Milestone is pursuing a single-study sNDA registration pathway. This is a positive clinical milestone for a $134M market cap biotech with an approved product and a new indication opportunity.
Key Facts
- First patient enrolled in Phase 3 ReVeRA-301 trial for etripamil in AFib-RVR
- Trial uses same 70 mg repeat-dose regimen already FDA-approved for PSVT (CARDAMYST)
- Milestone pursuing single-study sNDA registration pathway for AFib-RVR
- Primary endpoint: reduction in ventricular rate within 30 minutes
- Phase 2 data (ReVeRA-201) showed 70 mg dose reduced VR and improved symptom relief
- AFib affects over 6M patients in the U.S.; 30-40% experience RVR episodes requiring urgent care
- Market cap: $134M; analyst consensus 83% bullish (10 Buy, 2 Hold)
Financial Impact
No financial figures provided in the press release. AFib-RVR represents a large addressable market (30-40% of 6M+ AFib patients in U.S. with RVR episodes).
Risk Factors
- Phase 3 trial may fail to meet primary endpoint
- Enrollment delays or slower-than-expected site activation
- Regulatory pathway via single-study sNDA carries higher approval risk
- Competition from existing AFib-RVR treatments (IV beta blockers, calcium channel blockers, cardioversion)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3349033 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | 8-K | $1.20 $0.7794 | ▼ −35.05% | ▼ −35.65% | $0.6444 (−46.30%) |
Aug 21, 2026 9w ago | Press Release | $1.06 $0.9178 | ▼ −13.00% | ▼ −12.48% | $0.6444 (−38.92%) |
Aug 12, 2026 10w ago | 8-K | $1.13 $1.05 | ▲ +6.67% | ▲ +4.77% | $0.6444 (+42.72%) |
May 26, 2026 21w ago | EFFECT | $1.40 $1.28 | ▲ +8.57% | ▲ +6.62% | $0.6444 (+53.97%) |
May 13, 2026 23w ago | S-3 | $1.63 $1.27 | ▲ +22.09% | ▲ +21.23% | $0.6444 (+60.47%) |
May 13, 2026 23w ago | 8-K | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6444 (−62.53%) |
May 13, 2026 23w ago | Press Release | $1.72 $1.27 | ▼ −26.16% | ▼ −25.55% | $0.6444 (−62.53%) |
Mar 20, 2026 31w ago | Press Release | $1.36 $2.04 | ▲ +50.00% | ▲ +40.68% | $0.6444 (−52.62%) |
Mar 16, 2026 32w ago | Press Release | $1.69 $2.03 | ▲ +20.12% | ▲ +16.34% | $0.6444 (−61.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers